Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine

Taizo Hibi, Masahiro Shinoda, Osamu Itano, Yuukou Kitagawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Significant achievements in the organ replacement approach for malignancies over the last 2 decades opened new horizons, and the age of Transplant Oncology has dawned. The indications of liver transplantation for malignancies have been carefully expanded by a strict patient selection to assure comparable outcomes with non-malignant diseases. Currently, the Milan criteria, gold standard for hepatocellular carcinoma, are being challenged by high-volume centers worldwide. Neoadjuvant chemoradiation therapy and liver transplantation for unresectable hilar cholangiocarcinoma has been successful in specialized institutions. For other primary and metastatic liver tumors, clinical evidence to establish standardized criteria is lacking. Intestinal and multivisceral transplantation is an option for low-grade neoplasms deemed unresectable by conventional surgery. However, the procedure itself is in the adolescent stage. Solid organ transplantation for malignancies inevitably suffers from triple distress, i.e., oncological, immunological, and technical. Organ bioengineering and regenerative medicine should serve as the triple threat therapy and revolutionize Transplant Oncology.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalOrganogenesis
Volume10
Issue number2
DOIs
Publication statusPublished - 2014 Apr 1

Fingerprint

Bioengineering
Regenerative Medicine
Liver
Transplantation (surgical)
Transplants
Oncology
Neoplasms
Liver Transplantation
Klatskin Tumor
Surgery
Tumors
Neoadjuvant Therapy
Organ Transplantation
Patient Selection
Hepatocellular Carcinoma
Transplantation

Keywords

  • Autotransplantation
  • Intestinal transplantation
  • Liver transplantation
  • Malignant neoplasm
  • Multivisceral transplantation
  • Transplant oncology

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Transplantation
  • Biomedical Engineering

Cite this

Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. / Hibi, Taizo; Shinoda, Masahiro; Itano, Osamu; Kitagawa, Yuukou.

In: Organogenesis, Vol. 10, No. 2, 01.04.2014, p. 241-249.

Research output: Contribution to journalArticle

@article{c42a0aa84ed84d82b2aa5cd5dc0849b0,
title = "Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine",
abstract = "Significant achievements in the organ replacement approach for malignancies over the last 2 decades opened new horizons, and the age of Transplant Oncology has dawned. The indications of liver transplantation for malignancies have been carefully expanded by a strict patient selection to assure comparable outcomes with non-malignant diseases. Currently, the Milan criteria, gold standard for hepatocellular carcinoma, are being challenged by high-volume centers worldwide. Neoadjuvant chemoradiation therapy and liver transplantation for unresectable hilar cholangiocarcinoma has been successful in specialized institutions. For other primary and metastatic liver tumors, clinical evidence to establish standardized criteria is lacking. Intestinal and multivisceral transplantation is an option for low-grade neoplasms deemed unresectable by conventional surgery. However, the procedure itself is in the adolescent stage. Solid organ transplantation for malignancies inevitably suffers from triple distress, i.e., oncological, immunological, and technical. Organ bioengineering and regenerative medicine should serve as the triple threat therapy and revolutionize Transplant Oncology.",
keywords = "Autotransplantation, Intestinal transplantation, Liver transplantation, Malignant neoplasm, Multivisceral transplantation, Transplant oncology",
author = "Taizo Hibi and Masahiro Shinoda and Osamu Itano and Yuukou Kitagawa",
year = "2014",
month = "4",
day = "1",
doi = "10.4161/org.29245",
language = "English",
volume = "10",
pages = "241--249",
journal = "Organogenesis",
issn = "1547-6278",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine

AU - Hibi, Taizo

AU - Shinoda, Masahiro

AU - Itano, Osamu

AU - Kitagawa, Yuukou

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Significant achievements in the organ replacement approach for malignancies over the last 2 decades opened new horizons, and the age of Transplant Oncology has dawned. The indications of liver transplantation for malignancies have been carefully expanded by a strict patient selection to assure comparable outcomes with non-malignant diseases. Currently, the Milan criteria, gold standard for hepatocellular carcinoma, are being challenged by high-volume centers worldwide. Neoadjuvant chemoradiation therapy and liver transplantation for unresectable hilar cholangiocarcinoma has been successful in specialized institutions. For other primary and metastatic liver tumors, clinical evidence to establish standardized criteria is lacking. Intestinal and multivisceral transplantation is an option for low-grade neoplasms deemed unresectable by conventional surgery. However, the procedure itself is in the adolescent stage. Solid organ transplantation for malignancies inevitably suffers from triple distress, i.e., oncological, immunological, and technical. Organ bioengineering and regenerative medicine should serve as the triple threat therapy and revolutionize Transplant Oncology.

AB - Significant achievements in the organ replacement approach for malignancies over the last 2 decades opened new horizons, and the age of Transplant Oncology has dawned. The indications of liver transplantation for malignancies have been carefully expanded by a strict patient selection to assure comparable outcomes with non-malignant diseases. Currently, the Milan criteria, gold standard for hepatocellular carcinoma, are being challenged by high-volume centers worldwide. Neoadjuvant chemoradiation therapy and liver transplantation for unresectable hilar cholangiocarcinoma has been successful in specialized institutions. For other primary and metastatic liver tumors, clinical evidence to establish standardized criteria is lacking. Intestinal and multivisceral transplantation is an option for low-grade neoplasms deemed unresectable by conventional surgery. However, the procedure itself is in the adolescent stage. Solid organ transplantation for malignancies inevitably suffers from triple distress, i.e., oncological, immunological, and technical. Organ bioengineering and regenerative medicine should serve as the triple threat therapy and revolutionize Transplant Oncology.

KW - Autotransplantation

KW - Intestinal transplantation

KW - Liver transplantation

KW - Malignant neoplasm

KW - Multivisceral transplantation

KW - Transplant oncology

UR - http://www.scopus.com/inward/record.url?scp=84907531971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907531971&partnerID=8YFLogxK

U2 - 10.4161/org.29245

DO - 10.4161/org.29245

M3 - Article

C2 - 24836922

AN - SCOPUS:84907531971

VL - 10

SP - 241

EP - 249

JO - Organogenesis

JF - Organogenesis

SN - 1547-6278

IS - 2

ER -